Chronic Treatment with Oxcarbazepine Attenuates Its Anticonvulsant Effect in the Maximal Electroshock Model in Mice

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 27

PMID 38928457

Authors

Kinga Borowicz-Reutt

Monika Banach

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to assess the impact of acute and chronic treatment with oxcarbazepine on its anticonvulsant activity, neurological adverse effects, and protective index in mice. Oxcarbazepine was administered in four protocols: once or twice daily for one week (7 × 1 or 7 × 2) and once or twice daily for two weeks (14 × 1 or 14 × 2). A single dose of the drug was employed as a control. The anticonvulsant effect was evaluated in the maximal electroshock test in mice. Motor and long-term memory impairment were assessed using the chimney test and the passive avoidance task, respectively. The concentrations of oxcarbazepine in the brain and plasma were determined via high-performance liquid chromatography. Two weeks of oxcarbazepine treatment resulted in a significant reduction in the anticonvulsant (in the 14 × 1; 14 × 2 protocols) and neurotoxic (in the 14 × 2 schedule) effects of this drug. In contrast, the protective index for oxcarbazepine in the 14 × 2 protocol was found to be lower than that calculated for the control. No significant deficits in memory or motor coordination were observed following repeated administration of oxcarbazepine. The plasma and brain concentrations of this anticonvulsant were found to be significantly higher in the one-week protocols. Chronic treatment with oxcarbazepine may result in the development of tolerance to its anticonvulsant and neurotoxic effects, which appears to be dependent on pharmacodynamic mechanisms.

Citing Articles

Subchronic Treatment with CBZ Transiently Attenuates Its Anticonvulsant Activity in the Maximal Electroshock-Induced Seizure Test in Mice.

Banach M, Borowicz K Int J Mol Sci. 2025; 25(24.

PMID: 39769325 PMC: 11677119. DOI: 10.3390/ijms252413563.

References

Loscher W . Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011; 20(5):359-68. DOI: 10.1016/j.seizure.2011.01.003. View

Dusanter C, Houot M, Mere M, Denos M, Samson S, Herlin B . Cognitive effect of antiseizure medications in medial temporal lobe epilepsy. Eur J Neurol. 2023; 30(12):3692-3702. DOI: 10.1111/ene.16050. View

Schmidt D, Loscher W . Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005; 46(6):858-77. DOI: 10.1111/j.1528-1167.2005.54904.x. View

LITCHFIELD Jr J, WILCOXON F . A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96(2):99-113. View

Sabers A, Moller A, Dam M, Smed A, Arlien-Soborg P, BUCHMAN J . Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand. 1995; 92(1):19-27. DOI: 10.1111/j.1600-0404.1995.tb00461.x. View

Rissardo J, Caprara A . Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review. Clin Neuropharmacol. 2020; 43(3):66-80. DOI: 10.1097/WNF.0000000000000387. View

Agarwal N, Agarwal N, Mediratta P, Sharma K . Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. Seizure. 2011; 20(3):257-62. DOI: 10.1016/j.seizure.2010.12.006. View

Abou-Khalil B . Update on Antiseizure Medications 2022. Continuum (Minneap Minn). 2022; 28(2):500-535. DOI: 10.1212/CON.0000000000001104. View

Schmidt D . How reliable is early treatment response in predicting long-term seizure outcome?. Epilepsy Behav. 2007; 10(4):588-94. DOI: 10.1016/j.yebeh.2007.02.011. View

10.

Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y . Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10-hydroxycarbamazepine. Neurosci Lett. 2005; 390(1):48-53. DOI: 10.1016/j.neulet.2005.07.049. View

11.

Loscher W, Fiedler M . The role of technical, biological, and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VII. Seasonal influences on anticonvulsant drug actions in mouse models of generalized seizures. Epilepsy Res. 2000; 38(2-3):231-48. DOI: 10.1016/s0920-1211(99)00095-9. View

12.

Loscher W . The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia. 2007; 48(7):1245-58. DOI: 10.1111/j.1528-1167.2007.01093.x. View

13.

Tecoma E . Oxcarbazepine. Epilepsia. 1999; 40 Suppl 5:S37-46. DOI: 10.1111/j.1528-1157.1999.tb00918.x. View

14.

Shorvon S . Oxcarbazepine: a review. Seizure. 2000; 9(2):75-9. DOI: 10.1053/seiz.2000.0391. View

15.

Mandrioli R, Mercolini L . Metabolism of Drugs Used in the Therapy of Seizures: An Analytical Point of View. Part 1. Curr Drug Metab. 2017; 18(8):735-756. DOI: 10.2174/1389200218666170406115350. View

16.

Li Z, Zhao X, Zhang G, Xi C, Yang L . Efficacy of levetiracetam combined with oxcarbazepine in the treatment of adults with temporal lobe epilepsy and its impact on memory and cognitive function. Am J Transl Res. 2024; 16(3):1009-1017. PMC: 10994801. DOI: 10.62347/KNTE8578. View

17.

Zeng Q, Fan T, Zhu P, He R, Bao Y, Zheng R . Comparative Long-Term Effectiveness of a Monotherapy with Five Antiepileptic Drugs for Focal Epilepsy in Adult Patients: A Prospective Cohort Study. PLoS One. 2015; 10(7):e0131566. PMC: 4493091. DOI: 10.1371/journal.pone.0131566. View

18.

Banach M, Borowicz K . Effects of Chronic Lamotrigine Administration on Maximal Electroshock- Induced Seizures in Mice. CNS Neurol Disord Drug Targets. 2015; 14(7):855-62. DOI: 10.2174/1871527314666150225141642. View

19.

Borowicz K, Luszczki J, Czuczwar S . SIB 1893, a selective mGluR5 receptor antagonist, potentiates the anticonvulsant activity of oxcarbazepine against amygdala-kindled convulsions in rats. Pol J Pharmacol. 2004; 56(4):459-64. View

20.

Suo G, Zheng Y, Wu Y, Tang J . Effects of levetiracetam and oxcarbazepine monotherapy on intellectual and cognitive development in children with benign epilepsy with centrotemporal spikes. Acta Neurol Belg. 2021; 121(5):1265-1273. PMC: 8443489. DOI: 10.1007/s13760-021-01613-5. View